Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Overexpression of DNA polymerase beta results in an increased rate of frameshift mutations during base excision repair.

Chan K, Houlbrook S, Zhang QM, Harrison M, Hickson ID, Dianov GL.

Mutagenesis. 2007 May;22(3):183-8. Epub 2007 Jan 31.

PMID:
17267816
2.

Isolation of a small molecule inhibitor of DNA base excision repair.

Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S, Talbot DC, Hammonds T, Freemont PA, Sternberg MJ, Dianov GL, Hickson ID.

Nucleic Acids Res. 2005 Aug 19;33(15):4711-24. Print 2005.

3.
5.

Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.

Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmén J, Anttila M, Ganesan TS, Harris AL, Talbot DC.

Cancer Chemother Pharmacol. 2000;46(1):27-34.

PMID:
10912574
6.

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.

Braybrooke JP, Propper DJ, O'Byrne KJ, Koukourakis MI, Patterson AV, Houlbrook S, Love SD, Varcoe S, Taylor M, Ganesan TS, Talbot DC, Harris AL.

Br J Cancer. 2000 Jul;83(2):219-24.

7.

Synthesis and cytotoxic activity of thiazolyl indolequinones.

Moody CJ, Roffey JR, Swann E, Lockyer S, Houlbrook S, Strafford IJ.

Anticancer Drugs. 1999 Jul;10(6):577-89.

PMID:
10885906
8.

Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen.

Braybrooke JP, Houlbrook S, Crawley JE, Propper DJ, O'Byrne KJ, Stratford IJ, Harris AL, Shuker DE, Talbot DC.

Cancer Chemother Pharmacol. 2000;45(2):111-9.

PMID:
10663625
9.

Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay.

Chao D, Bahl P, Houlbrook S, Hoy L, Harris A, Austyn JM.

Br J Cancer. 1999 Dec;81(8):1280-4.

10.

The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.

Turley H, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson ID, Gatter K, Harris AL.

Br J Cancer. 1997;75(9):1340-6.

11.

Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines.

Houlbrook S, Harris AL, Carmichael J, Stratford IJ.

Anticancer Res. 1996 Jul-Aug;16(4A):1603-10.

PMID:
8712677
12.

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.

Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL, Hickson ID.

Br J Cancer. 1995 Dec;72(6):1454-61. Erratum in: Br J Cancer 1996 Oct;74(7):1154.

13.

Synthesis and biological activity of thiazolylindolequinones, analogues of the natural product BE 10988.

Moody CJ, Swann E, Houlbrook S, Stephens MA, Stratford IJ.

J Med Chem. 1995 Mar 17;38(6):1039-43.

PMID:
7699696
14.

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, Stratford IJ, Carmichael J.

Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):369-72.

PMID:
8195035
15.
16.
17.

Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.

Kirk J, Houlbrook S, Stuart NS, Stratford IJ, Harris AL, Carmichael J.

Eur J Cancer. 1993;29A(8):1152-7.

PMID:
8518026
18.

High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.

Stuart NS, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J.

Br J Cancer. 1992 Nov;66(5):833-9.

19.

The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?

Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE.

Biochem Pharmacol. 1992 Aug 4;44(3):409-12.

PMID:
1510692
20.

Tissue plasminogen activators in breast cancer.

Layer GT, Burnand KG, Gaffney PJ, Cederholm-Williams SA, Mahmoud M, Houlbrook S, Pattison M.

Thromb Res. 1987 Mar 1;45(5):601-7.

PMID:
3109062

Supplemental Content

Loading ...
Support Center